Revvity Enters Definitive Agreement to Acquire ACD/Labs-March 2024-www.financetom.com

Revvity Enters Definitive Agreement to Acquire ACD/Labs

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Revvity Enters Definitive Agreement to Acquire ACD/Labs

Nov 10, 2025 5:47 AM

08:22 AM EST, 11/10/2025 (MT Newswires) -- Revvity ( RVTY ) said Monday it has entered into a definitive agreement to acquire ACD/Labs.

Financial terms weren't disclosed.

Revvity ( RVTY ) said it will integrate ACD/Labs' technologies with its Revvity Signals platform to offer a unified software-as-a-service experience to clients, adding it intends to complete the acquisition in late Q4.

Shares of Revvity ( RVTY ) were down 2.3% in recent Monday premarket activity.

Previous page： Oncology Institute Q3 revenue jumps, partly on organic growth in Florida, Oregon Next page： Precigen Q3 Loss Widens, Revenue Rises

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Oncology Institute Q3 revenue jumps, partly on organic growth in Florida, Oregon

Nov 13, 2025

Overview * Oncology Institute ( TOI ) Q3 revenue rises 36.7% yr/yr, driven by organic growth in Florida, Oregon * Net loss for Q3 widens slightly to $16.5 mln compared to $16.1 mln last year * The cancer clinics operator updates full-year revenue guidance to $495-$505 mln Outlook * Company updates full-year revenue guidance to $495 mln-$505 mln, from prior...

Precigen Q3 Loss Widens, Revenue Rises

Nov 13, 2025

04:30 PM EST, 11/13/2025 (MT Newswires) -- Precigen ( PGEN ) reported a Q3 loss late Thursday of $1.06 per diluted share, widening from a loss of $0.09 a year earlier. Revenue for the three months ended Sept. 30 was $2.9 million, up from $953,000 a year earlier. ...

ORIC Pharmaceuticals Q3 net loss narrows to $32.6 mln

Nov 13, 2025

Overview * ORIC Pharmaceuticals ( ORIC ) reports Q3 net loss of $32.6 mln, with decreased operating expenses * Cash and investments of $413 mln expected to fund operations into 2H 2028 Outlook * Company anticipates cash to fund operations into 2H 2028 Result Drivers * LEADERSHIP APPOINTMENT - Appointment of Kevin Brodbeck, PhD, as Chief Technical Officer to support...

Kodiak Sciences Q3 net loss widens

Nov 13, 2025

Overview * Kodiak Sciences ( KOD ) reports Q3 net loss of $61.5 mln, increased from $43.9 mln last year * R&D expenses rise to $50.5 mln in Q3, driven by active clinical studies * Kodiak ends Q3 with $72 mln in cash, down from $168 mln last year Outlook * Kodiak expects topline data for tarcocimab's Phase 3 GLOW2...